Bio-Rad Launches RT-PCR Assays to Track SARS-CoV-2 Variants More Rapidly and Cost-Effectively
By LabMedica International staff writers Posted on 22 Apr 2021 |
Illustration
Bio-Rad Laboratories (Hercules, CA, USA) has launched the SARS-CoV-2 Variant RT-PCR Assays for research use only (RUO).
The assays can detect SARS-CoV-2 (the virus associated with COVID-19) variants of concern, including P.1, B.1.351, and B.1.1.7, by distinguishing specific mutations in SARS-CoV-2 using reverse transcription PCR (RT-PCR) often prior to a next generation sequencing (NGS) workflow for confirmation.
With the emergence of several SARS-CoV-2 variants of concern, public health researchers are looking for a quicker way to track the spread of these variants in a population. Laboratories that use NGS to track COVID-19 variants can detect these mutations more quickly and cost-effectively with the SARS-CoV-2 Variant RT-PCR Assays to more rapidly prioritize which samples to submit for NGS.
"We are pleased to introduce our SARS-CoV-2 Variant RT-PCR Assays to enable detection of mutations in these new variants more quickly and cost-effectively by laboratories using NGS to track COVID-19 variants," said John Randall, Bio-Rad Vice President Marketing, Life Science Group. “The assays join Bio-Rad’s offering of research and testing products that are helping in the fight against COVID-19.”
The assays can detect SARS-CoV-2 (the virus associated with COVID-19) variants of concern, including P.1, B.1.351, and B.1.1.7, by distinguishing specific mutations in SARS-CoV-2 using reverse transcription PCR (RT-PCR) often prior to a next generation sequencing (NGS) workflow for confirmation.
With the emergence of several SARS-CoV-2 variants of concern, public health researchers are looking for a quicker way to track the spread of these variants in a population. Laboratories that use NGS to track COVID-19 variants can detect these mutations more quickly and cost-effectively with the SARS-CoV-2 Variant RT-PCR Assays to more rapidly prioritize which samples to submit for NGS.
"We are pleased to introduce our SARS-CoV-2 Variant RT-PCR Assays to enable detection of mutations in these new variants more quickly and cost-effectively by laboratories using NGS to track COVID-19 variants," said John Randall, Bio-Rad Vice President Marketing, Life Science Group. “The assays join Bio-Rad’s offering of research and testing products that are helping in the fight against COVID-19.”
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants